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1726-4The role of red blood cells in cardiovascular diseaseMany chronic illnesses show a sex difference, not only in
the incidence but also in the severity of these diseases. For
example, women, especially before menopause, have a sig-
nificantly lower risk of cardiovascular disease (CVD) and
chronic kidney disease than men.1 However, to date, there is
uncertainty as to why sex differences influence physiological,
pathological, and pathophysiological changes, partly because
these chronic illnesses are complex diseases of multifactorial
origin.2 In addition, an interaction between each other might
slow down or accelerate the processes of these diseases.
Among these factors, sex hormones are considered of critical
importance. Therefore, attention recently has been focused on
understanding the features of sex hormones relevant to the
physiological, pathological, and pathophysiological features of
various kinds of systems, including Taskin et al's3 study in this
issue.
Evidence has shown that oral contraceptives (OCs) might
induce extremely rare CVD and venous thromboembolism in
young healthy women, however, the risk of CVD was dra-
matically and significantly increased in smoking and/or older
women (35 years).4 Although the underlying mechanism of
the increased risk in smoking and/or older women is unknown,
it might involve female sex hormones and smoking, and their
interaction, which affect the metabolism and possibly impair
homeostasis of coagulation.4
The carbonic anhydrase (CA) enzymes play an important
role in CO2 influx and efflux by red blood cells.
5 The reason
for briefly considering the history of modeling CO2/HCO3
e
equilibrium under physiological conditions is that the effects
of CA enzymes, by their nature, depend on time and space.5
This CO2/HCO3
e buffer system is critical to maintain cellular
function, because it regulates intracellular pH, which is also
important for metabolism and homeostasis.6 However, the
term metabolon should be introduced, because CA enzymes
work as a metabolon. A metabolon is described as a complex
of enzyme systems that catalyze a series of reactions in a
metabolic pathway.5 A product of one enzyme is a substrate of
the next; therefore, the channeling of intermediates increases
their effective concentrations, permitting the overall process to
proceed with a much higher efficiency than if the enzymes
were spatially dispersed.5 In addition, mammalian cells
express 16 isoforms of CA, found in the cytosol (CAI, CAII,
CAIII, CAVII, CAXIII), membrane-associated (CAIV, CAIX,x.doi.org/10.1016/j.jcma.2015.04.007
901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical AssCAXII, CAXIV, CAXV), in the mitochondria (CAV), and
secreted into saliva and milk (CAVI).6
We do not know the rationale of Taskin et al's3 study,
because we wonder why they studied CA enzymes activity of
red blood cells (RBC) in women with/without smoking. Taskin
et al3 found that smoking might significantly increase CAI and
CAII enzyme activity of RBC, and female sex hormones had a
strongly inhibitory effect on CA enzyme activity; and this
inhibitory effect was much more apparent in smoking women.
However, the authors also found that the inhibitory effect of
female sex hormones on CA enzyme activity was varied by
different types of female sex hormones and this inhibitory
effect of female sex hormones was also varied by different
subtypes of CA enzymes. This study is interesting, because it
explains why some kinds of OCs contributed to a higher risk
of CVD, even in those women who believed that they were not
contraindicated to receive OC treatment. In addition, the risk
of CVD was dramatically increased in smoking women, and
even when these women used the comparatively safe OCs.
However, is it true that CA enzyme activity involves the risk of
CVD? More evidence might be needed. One report published
in 2007, showed that CA might be mediated by the hyper-
trophic response of cardiac myocytes to phenylephrine, sug-
gesting that CA inhibition may represent an effective
therapeutic approach toward mitigation of the hypertrophic
phenotype.7 If female sex hormones function as CA inhibitors,
and CA inhibitions in the RBC contribute to a lower risk of
CVD, such as cardiac hypertrophy, this may well explain why
women, especially before menopause, have a significantly
lower risk of CVD. These premenopausal women indeed have
higher levels of female sex hormones than age-matched men,8
suggesting that these endogenous female sex hormones which
are beneficial in protection against the occurrence of CVD,
may be significantly mediated by decreasing CA enzyme
activity of RBC. In addition, smoking can elevate CA enzyme
activity of RBC in these women significantly. It provides an
acceptable answer to respond to why smoking has a sig-
nificantly higher risk of CVD. By contrast, Taskin et al's3 study
showed that exogenous and supraphysiologically high levels
of female sex hormones used in younger women and the
effects of these female sex hormones still function as CA
enzyme inhibitors. Moreover, CA enzyme inhibition was
female sex hormone dose dependent. Why does the CVD riskociation. All rights reserved.
500 Editorial / Journal of the Chinese Medical Association 78 (2015) 499e500paradoxically increase in these younger women? This result
makes the audience confused about the role of CA enzyme
activity of RBC in the risk of CVD. Is it a hero or villain?
In conclusion, CVD is a complex disease, and it is difficult
to use a limited number of factors to explain its complicated
features. However, we still believe that this article provided by
Taskin et al3 is of value, because RBC (containing CA
enzyme) might be a potential target in place of platelets for the
prevention of CVD, if Taskin et al's3 findings could be further
and clearly explored.
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